Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gabriel Sardi

Cardiovascular Disease Easton, MD Medical Doctor

NPI 1326255712 CMS profile 856369

500 Cadmus Ln, Suite 207, Easton, MD 21601

Open in the dashboard

General payments

$5,358

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gabriel Sardi of Easton, MD is reported in the CMS Open Payments database as having received $5,358 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,322 22
2024 General $1,033 29
2023 General $608 22
2022 General $552 23
2021 General $696 23
2020 General $527 20
2019 General $619 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gabriel Sardi
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Gabriel Sardi were reported at $1,322. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Gabriel Sardi Cardiovascular Disease median Middle half National median
2019 $619 $450 $127–$1,392 $163
2020 $527 $242 $77–$751 $114
2021 $696 $335 $101–$1,037 $132
2022 $552 $395 $121–$1,211 $149
2023 $608 $443 $136–$1,283 $160
2024 $1,033 $450 $136–$1,323 $164
2025 $1,322 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $961 28 payments
  2. Medtronic, Inc. $687 19 payments
  3. Shockwave Medical, Inc $411 3 payments
  4. Amgen Inc. $361 8 payments
  5. Novartis Pharmaceuticals Corporation $361 20 payments
  6. Boston Scientific Corporation $337 13 payments
  7. Edwards Lifesciences Corporation $298 2 payments
  8. Pfizer Inc. $257 9 payments
  9. Abbott Laboratories $252 8 payments
  10. AstraZeneca Pharmaceuticals LP $228 13 payments
  11. Other $1,206 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,358 165 payments
Products named General payments · program years 2019–2025
  1. LifeVest $961 28 payments
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $411 3 payments
  3. SAPIEN 3 Ultra RESILIA $298 2 payments
  4. Repatha $273 7 payments
  5. BRILINTA $208 12 payments
  6. ELIQUIS $158 7 payments
  7. ENTRESTO $154 10 payments
  8. COBALT DR MRI SURESCAN $146 2 payments
  9. LEQVIO $139 6 payments
  10. Resolute $137 3 payments
  11. Other $2,392 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,078

Median for Internal Medicine: 777

Drug cost

$215,423

Median for Internal Medicine: $73,373

Branded share of claims

30.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 58 $58,613
Repatha Sureclick Evolocumab Brand 40 $46,399
Eliquis Apixaban Brand 60 $44,785
Jardiance Empagliflozin Brand 46 $31,298
Brilinta Ticagrelor Brand 34 $18,773
Rosuvastatin Calcium Generic 135 $3,649
Ezetimibe Generic 61 $3,374
Atorvastatin Calcium Generic 120 $1,826
Metoprolol Succinate Generic 117 $1,812
Ranolazine Er Ranolazine Brand 12 $1,544

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$214,602

Medicare's payments for the services billed

Medicare patients

1,498

Average age 76

Services billed

2,834

702 women, 796 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 47%
Diabetes 39%
Atrial fibrillation 39%
Heart failure 38%
Chronic kidney disease 35%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $175
$175 40 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $125
$125 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $80
$80 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $24
$24 46 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record